» Articles » PMID: 9010274

IL-6 and Soluble IL-6 Receptors (sIL-6R and Sgp130) in Human Pleural Effusions: Massive IL-6 Production Independently of Underlying Diseases

Overview
Date 1997 Jan 1
PMID 9010274
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

IL-6, soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) levels were measured in sera and pleural effusions from 42 patients with metastatic carcinoma, non-Hodgkin's lymphoma, tuberculosis, cardiac failure and miscellaneous diseases. Pleural IL-6 levels measured by ELISA were very high in all patient groups (mean 34.8 +/- 15.3 ng/ml) without significant difference according to diseases. IL-6 was shown to be biologically active in a proliferative assay. Serum IL-6 levels were low (0.049 +/- 0.014 ng/ml) and did not correlate with pleural fluid levels. Pleural IL-6 levels correlated with the number of polymorphonuclear cells in pleural fluid (P < 0.03). Pleural sIL-6R levels (76 +/- 8 ng/ml) were always lower than serum levels (196 +/- 12 ng/ml; P < 0.0001) but correlated with them (P < 0.01). Pleural sIL-6R and albumin levels correlated (P < 0.01), suggesting a transudation of sIL-6R from the serum. Pleural sgp130 levels (10.9 +/- 1.0 ng/ml) were lower than serum levels (24.6 +/- 2.8 ng/ml; P < 0.002). After gel filtration of pleural fluid, the bulk of IL-6 (> 90%) was recovered in a 15,000-30,000 fraction, corresponding to the expected mol. wt of free IL-6. These results suggest a production and a sequestration of IL-6 in the pleural cavity in all studied conditions.

Citing Articles

A common secretomic signature across epithelial cancers metastatic to the pleura supports IL-6 axis therapeutic targeting.

Donnenberg V, Luketich J, Popov B, Bartlett D, Donnenberg A Front Immunol. 2024; 15:1404373.

PMID: 39114667 PMC: 11303180. DOI: 10.3389/fimmu.2024.1404373.


A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells.

Donnenberg V, Luketich J, Sultan I, Lister J, Bartlett D, Ghosh S Front Immunol. 2023; 14:1157697.

PMID: 37063842 PMC: 10097923. DOI: 10.3389/fimmu.2023.1157697.


Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity.

Donnenberg V, Wagner P, Luketich J, Bartlett D, Donnenberg A Front Immunol. 2022; 13:846235.

PMID: 35222439 PMC: 8873820. DOI: 10.3389/fimmu.2022.846235.


Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications.

Donnenberg A, Luketich J, Donnenberg V Oncotarget. 2019; 10(60):6456-6465.

PMID: 31741710 PMC: 6849644. DOI: 10.18632/oncotarget.27290.


Treatment of malignant pleural effusions: the case for localized immunotherapy.

Donnenberg A, Luketich J, Dhupar R, Donnenberg V J Immunother Cancer. 2019; 7(1):110.

PMID: 30999958 PMC: 6472034. DOI: 10.1186/s40425-019-0590-4.